Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.

Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, Boellaard R, Du S, Hayes W, Smith R, Windhorst AD, Hendrikse NH, Poot A, Vugts DJ, Thunnissen E, Morin P, Lipovsek D, Donnelly DJ, Bonacorsi SJ, Velasquez LM, de Gruijl TD, Smit EF, de Langen AJ.

Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y.

2.

LC-MS/MS bioanalysis of plasma 1, 14-tetradecanedioic acid and 1, 16-hexadecanedioic acid as candidate biomarkers for organic anion-transporting polypeptide mediated drug-drug interactions.

Santockyte R, Kandoussi H, Chen W, Zheng N, Venkatarangan L, Gan J, Shen H, Bonacorsi SJ, Easter J, Burrell R, Zhang YJ, Zeng J.

Bioanalysis. 2018 Sep 1;10(18):1473-1485. doi: 10.4155/bio-2018-0170. Epub 2018 Sep 14.

PMID:
30215261
3.

Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.

Donnelly DJ, Smith RA, Morin P, Lipovšek D, Gokemeijer J, Cohen D, Lafont V, Tran T, Cole EL, Wright M, Kim J, Pena A, Kukral D, Dischino DD, Chow P, Gan J, Adelakun O, Wang XT, Cao K, Leung D, Bonacorsi SJ Jr, Hayes W.

J Nucl Med. 2018 Mar;59(3):529-535. doi: 10.2967/jnumed.117.199596. Epub 2017 Oct 12.

4.

Synthesis of unlabelled and stable-isotope-labelled glucuronide metabolites of dapagliflozin and synthesis of stable-isotope-labelled dapagliflozin.

Cao K, Brailsford JA, Yao M, Caceres-Cortes J, Espina R, Bonacorsi SJ Jr.

J Labelled Comp Radiopharm. 2017 Mar;60(3):150-159. doi: 10.1002/jlcr.3484. Epub 2017 Feb 1.

PMID:
27868223
5.

Tissue distribution and tumor uptake of folate receptor-targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration.

Shen H, Wang L, Chen W, Menard K, Hong Y, Tian Y, Bonacorsi SJ, Humphreys WG, Lee FY, Gan J.

Acta Pharm Sin B. 2016 Sep;6(5):460-467. Epub 2016 Aug 11.

6.

The syntheses of isotopically labelled CB-1 antagonists for the treatment of obesity.

Tran SB, Maxwell BD, Burrell R, Bonacorsi SJ Jr.

J Labelled Comp Radiopharm. 2016 Dec;59(14):665-672. doi: 10.1002/jlcr.3433. Epub 2016 Sep 14.

PMID:
27624665
7.

The synthesis and analysis of [phenyl-14 C(U)]BMS-770767 and [13 C6 ]BMS-770767 for use in discovery biotransformation, human ADME and bioanalytical studies.

Maxwell BD, Bonacorsi SJ Jr.

J Labelled Comp Radiopharm. 2016 Dec;59(14):657-664. doi: 10.1002/jlcr.3428. Epub 2016 Jul 27.

PMID:
27460954
8.

The syntheses of [(14) C]BMS-823778 for use in a human ADME clinical study and of [(13) CD3 (13) CD2 ]BMT-094817, a stable-isotope labeled standard of a newly detected human metabolite.

Maxwell BD, Tran SB, Lago M, Li J, Bonacorsi SJ Jr.

J Labelled Comp Radiopharm. 2016 May 30;59(6):255-9. doi: 10.1002/jlcr.3383.

PMID:
27169762
9.

Synthesis of isotopically labeled daclatasvir for use in human clinical studies.

Easter JA, Burrell RC, Bonacorsi SJ Jr.

J Labelled Comp Radiopharm. 2016 Apr;59(4):164-70. doi: 10.1002/jlcr.3386. Epub 2016 Mar 10.

PMID:
26968868
10.

Synthesis of stable isotope-labeled epothilone D using a degradation-reconstruction approach.

Burrell RC, Turley WA, Bonacorsi SJ Jr.

J Labelled Comp Radiopharm. 2015 Jul;58(9):361-9. doi: 10.1002/jlcr.3312. Epub 2015 Jul 8.

PMID:
26158758
11.

The synthesis of 14C-labeled N-succinimidyl-3-maleimidopropionate, a linker molecule for PEGylated biologics.

Cao K, Maxwell BD, Bonacorsi SJ.

J Labelled Comp Radiopharm. 2014 Oct;57(12):667-9. doi: 10.1002/jlcr.3225. Epub 2014 Oct 10.

PMID:
25303408
12.

Synthesis of carbon-14 and stable isotope labeled Avagacestat: a novel gamma secretase inhibitor for the treatment of Alzheimer's disease.

Burrell RC, Easter JA, Cassidy MP, Gillman KW, Olson RE, Bonacorsi SJ.

J Labelled Comp Radiopharm. 2014 Aug;57(10):600-5. doi: 10.1002/jlcr.3224. Epub 2014 Sep 5.

PMID:
25196195
13.

Synthesis of a stable isotopically labeled universal surrogate peptide for use as an internal standard in LC-MS/MS bioanalysis of human IgG and Fc-fusion protein drug candidates.

Voronin K, Allentoff AJ, Bonacorsi SJ Jr, Mapelli C, Gong SX, Lee V, Riexinger D, Sanghvi N, Jiang H, Zeng J.

J Labelled Comp Radiopharm. 2014 Jul;57(9):579-83. doi: 10.1002/jlcr.3218. Epub 2014 Aug 4.

PMID:
25089024
14.

The synthesis of (14)C-labeled, (13)CD2-labeled saxagliptin, and its (13)CD2-labeled 5-hydroxy metabolite.

Tran SB, Maxwell BD, Cao K, Bonacorsi SJ.

J Labelled Comp Radiopharm. 2014 Mar;57(3):136-40. doi: 10.1002/jlcr.3179. Epub 2014 Feb 12.

PMID:
24519575
15.

Synthesis of [3α-(3) H] 17α-hydroxy pregnenolone and [3α-(3) H] pregnenolone.

Tian Y, Hong Y, Bonacorsi SJ, Balog A, Gong S.

J Labelled Comp Radiopharm. 2014 Jan;57(1):1-11. doi: 10.1002/jlcr.3114. Epub 2013 Oct 24.

PMID:
24448740
16.

An alternative and robust synthesis of [(13) C4 ]Baraclude® (entecavir).

Easter JA, Burrell RC, Bonacorsi SJ Jr.

J Labelled Comp Radiopharm. 2013 Oct;56(12):632-6. doi: 10.1002/jlcr.3064. Epub 2013 Jul 16.

PMID:
24285240
17.

Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.

Xu XS, Dueker SR, Christopher LJ, Lohstroh PN, Keung CF, Cao KK, Bonacorsi SJ, Cojocaru L, Shen JX, Humphreys WG, Stouffer B, Arnold ME.

Bioanalysis. 2012 Aug;4(15):1855-70. doi: 10.4155/bio.12.171.

PMID:
22943617
18.

Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.

Su H, Boulton DW, Barros A Jr, Wang L, Cao K, Bonacorsi SJ Jr, Iyer RA, Humphreys WG, Christopher LJ.

Drug Metab Dispos. 2012 Jul;40(7):1345-56. doi: 10.1124/dmd.112.045450. Epub 2012 Apr 10.

PMID:
22496391
19.

Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS).

Cömezoğlu SN, Ly VT, Zhang D, Humphreys WG, Bonacorsi SJ, Everett DW, Cohen MB, Gan J, Beumer JH, Beijnen JH, Schellens HM, Lappin G.

Drug Metab Pharmacokinet. 2009;24(6):511-22.

20.

Distinguishing a phosphate ester prodrug from its isobaric sulfate metabolite by mass spectrometry without the metabolite standard.

Wu ST, Cao K, Bonacorsi SJ Jr, Zhang H, Jemal M.

Rapid Commun Mass Spectrom. 2009 Oct;23(19):3107-13. doi: 10.1002/rcm.4228.

PMID:
19714709
21.

Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.

Christopher LJ, Cui D, Li W, Barros A Jr, Arora VK, Zhang H, Wang L, Zhang D, Manning JA, He K, Fletcher AM, Ogan M, Lago M, Bonacorsi SJ, Humphreys WG, Iyer RA.

Drug Metab Dispos. 2008 Jul;36(7):1341-56. doi: 10.1124/dmd.107.018234. Epub 2008 Apr 17.

PMID:
18420785
22.

Metabolism and disposition of dasatinib after oral administration to humans.

Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA.

Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17.

PMID:
18420784
23.

Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs.

Zhang D, Raghavan N, Chen SY, Zhang H, Quan M, Lecureux L, Patrone LM, Lam PY, Bonacorsi SJ, Knabb RM, Skiles GL, He K.

Drug Metab Dispos. 2008 Feb;36(2):303-15. Epub 2007 Nov 5.

PMID:
17984286
24.

Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans.

Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK, Iyer RA.

Drug Metab Dispos. 2006 Jun;34(6):961-70. Epub 2006 Mar 15.

PMID:
16540589

Supplemental Content

Loading ...
Support Center